- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Kyntra Bio, Inc.(KYNB)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for KYNB
11/13/2026: KYNB (1-star) is currently NOT-A-BUY. Pass it for now.
Kyntra Bio is a clinical-stage biopharmaceutical micro-cap stock focused on precision oncology and rare disease therapies. The company's primary strength lies in its promising pipeline candidate, FG-3246, an antibody-drug conjugate targeting CD46 for prostate cancer. Its main investment story centers on re-evaluating clinical potential following a major corporate restructuring and rebranding. However, high clinical execution risks, historical trial setbacks, and thin operating revenues present notable financial vulnerabilities. The stock suits speculative growth investors willing to monitor upcoming clinical readouts and cash burn metrics.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | The company is a micro-cap clinical-stage entity undergoing restructuring rather than a high-growth commercial enterprise. |
| Momentum investor | Strong fit while signal remains positive | Low share price and micro-cap status can occasionally spark sharp speculative rallies on clinical news. |
| Value investor | Weak fit | Ongoing operational losses and binary clinical risks make fundamental value assessment highly speculative. |
| Dividend investor | Weak fit | The company pays no dividends and prioritizes cash preservation for drug development. |
| Low-risk investor | Weak fit | High share price volatility and binary clinical trial outcomes expose investors to severe capital loss risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Micro-cap clinical-stage stocks experience extreme price swings driven by market sentiment and news. |
| Valuation risk | High | Valuation is heavily tied to speculative clinical milestones rather than stable earnings. |
| Competition risk (oncology and biopharma competition) | High | Well-capitalized pharmaceutical competitors easily outspend Kyntra Bio in clinical trials and commercialization. |
| Business quality | Medium | The pipeline holds scientific promise, but historical execution issues temper overall franchise quality. |
| Dividend income | Low / none | No dividend is paid or anticipated as all funds support R&D. |
| Execution risk | High | The company's survival depends on successfully executing complex Phase 2 clinical trials on a tight budget. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.93M USD | Price to earnings Ratio - | 1Y Target Price 38.5 |
Price to earnings Ratio - | 1Y Target Price 38.5 | ||
Volume (30-day avg) 24.6K shares | Beta 1.1 | 52 Weeks Range 3.34 - 10.47 | Updated Date 11/15/2026 |
52 Weeks Range 3.34 - 10.47 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.64 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Downtrend
The stock has experienced a sustained decline in price over recent periods.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -3% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Revenue and Collaborations | Milestone payments, licensing fees, and regional product sales collaboration revenues from partners like AstraZeneca. | Revenue is currently minimal and intermittent, relying heavily on partnership deals rather than steady product sales. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 61.35 | Enterprise Value 64.50M | Price to Sales(TTM) 3.02 |
Enterprise Value 64.50M | Price to Sales(TTM) 3.02 | ||
Enterprise Value to Revenue 13.97 | Enterprise Value to EBITDA 44.15 | Shares Outstanding 4.05M | Shares Floating 3.57M |
Shares Outstanding 4.05M | Shares Floating 3.57M | ||
Percent Insiders 2.21 | Percent Institutions 24.58 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

